|Bid||6.77 x 800|
|Ask||8.17 x 1000|
|Day's Range||6.73 - 7.24|
|52 Week Range||4.10 - 33.34|
|Beta (5Y Monthly)||-0.19|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 17, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VICTORIA, British Columbia, Jun 17, 2021--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced additional results from its in vivo hamster challenge efficacy study of TATX-03a PolyTope™ Therapy, a four monoclonal antibody cocktail being developed for the potential prevention and treatment of SARS-CoV-2, demonstrating reduced bronchitis and tracheitis inflammation severity. The Company concurrently announced optimization results of TATX-03 cocktai
VICTORIA, British Columbia, Jun 15, 2021--IMMUNOPRECISE ANTIBODIES LTD (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) today announced the results from in vitro characterizations investigating TATX-21, a novel potential first-in-class antibody for Atherosclerosis Cardiovascular Disease (ACVD), will be presented in partnering meetings at the 2021 BIO International Convention, June 14-18, 2021.
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, announced today that Dr. Yasmina Abdiche, Chief Scientific Officer, will resign effective July 1, 2021, to pursue other opportunities, and that the board of directors has appointed Dr. Ilse Roodink to take over the role of Chief Scientific Officer.